DHRM [Dehaier Medical Systems] 10-K: FORM 10-K þ For the fiscal year ended

[FORM 10-K þ For the fiscal year ended December 31, 2011 ¨ For the transition period from to . Dehaier Medical Systems Limited British Virgin Islands Not Applicable (State or other jurisdiction of incorporation or organization) (I.R.S. employer identification number) Room 501, Jiuzhou Plaza, 83 Fuxing Road Haidian District, Beijing 100856 People’s Republic of China +86 (10) 5166-0080 Securities registered] [List of Subsidiaries Dehaier Medical Systems Limited Subsidiary (Hong Kong): De-haier Medical Systems (Hong Kong) Limited Subsidiaries (PRC) Subsidiaries (U.S.) Breathcare LLC, incorporated in the state of Illinois Affiliate (PRC) Beijing Dehaier Technology Company Limited (controlled by certain executive officers; owns approximately 3.63% of PRC subsidiary)] [I, Ping Chen, certify that: (1) I have reviewed this Form 10-K of Dehaier Medical Systems Limited; (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [I, , certify that: (1) I have reviewed this Form 10-K of Dehaier Medical Systems Limited; (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with this Form 10-K period report of (2) The information contained in the this period report fairly presents, in all material respects, the financial condition and results of operations of Ping Chen Ping Chen] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with this Form 10-K period report of (2) The information contained in the this period report fairly presents, in all material respects, the financial condition and results of operations of Yanying (Aileen) Qi Yanying (Aileen) Qi Chief Financial Officer (Principal Financial Officer)]

SOL [ReneSola] 6-K: (Original Filing)

[ReneSola Ltd. Announces Fourth Quarter and Full Year 2011 Results Exceeds guidance with full year revenues of US$985.3 million; Exceeds guidance with record full year solar wafer and module shipments of 1.3 GW; Achieves full year gross profit margin of 9.7%; Achieves full year operating margin of 1.2% JIASHAN, China, March 16, 2012 Fourth Quarter 2011 Financial and Operating Highlights] []

By | 2016-03-27T11:37:48+00:00 March 19th, 2012|Categories: Chinese Stocks, SEC Original, SOL|Tags: , , , , , |0 Comments

CBPO [China Biologic Products] SC 13D/A: (Original Filing)

[REQUEST FOR STOCKHOLDER CONSENT TO ACTION Ms. Lin Ling Li lll@ctbb.com.cn DATED: MARCH 15, 2012 To : including all pages If you agree with the proposed action by written consent set forth herein, please sign the accompanying written consent which we will notify the Company in accordance with the Delaware General Corporation Law (the “DGCL”). Please return the signed written] [SCHEDULE 13D [Rule 13d-101] (Amendment No. 4)* CHINA BIOLOGIC PRODUCTS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 16938C106 (CUSIP Number) No. 14 East Hushan Road Tai'an City, Shandong 271000 People's Republic of China (86) 538-620-2306 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) March 14, 2012]

CBPO [China Biologic Products] SC 13D/A: REQUEST FOR STOCKHOLDER CONSENT TO ACTION Ms. Lin

[REQUEST FOR STOCKHOLDER CONSENT TO ACTION Ms. Lin Ling Li lll@ctbb.com.cn DATED: MARCH 15, 2012 To : including all pages If you agree with the proposed action by written consent set forth herein, please sign the accompanying written consent which we will notify the Company in accordance with the Delaware General Corporation Law (the “DGCL”). Please return the signed written] [SCHEDULE 13D [Rule 13d-101] (Amendment No. 4)* CHINA BIOLOGIC PRODUCTS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 16938C106 (CUSIP Number) No. 14 East Hushan Road Tai'an City, Shandong 271000 People's Republic of China (86) 538-620-2306 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) March 14, 2012]

MPEL [Melco Crown Entertainment] 6-K: (Original Filing)

[For Main Board listed issuers Next Day Disclosure Return (Equity issuer - changes in issued share capital and/or share buybacks) Melco Crown Entertainment Limited Name of listed issuer: 6883 Stock code: Date submitted: March 18, 2012 Section II must also be completed by a listed issuer where it has made a repurchase of shares which is discloseable under rule 10.06(4)(a).]

By | 2016-03-07T02:06:50+00:00 March 19th, 2012|Categories: Chinese Stocks, MPEL, SEC Original|Tags: , , , , , |0 Comments

MPEL [Melco Crown Entertainment] 6-K: For Main Board listed issuers Next Day Disclosure

[For Main Board listed issuers Next Day Disclosure Return (Equity issuer - changes in issued share capital and/or share buybacks) Melco Crown Entertainment Limited Name of listed issuer: 6883 Stock code: Date submitted: March 18, 2012 Section II must also be completed by a listed issuer where it has made a repurchase of shares which is discloseable under rule 10.06(4)(a).]

By | 2016-03-07T02:09:44+00:00 March 19th, 2012|Categories: Chinese Stocks, MPEL, Webplus ver|Tags: , , , , , |0 Comments
Skip to toolbar